YSL
This article was originally published in The Rose Sheet
Executive Summary
Sales increase 6.7% to $138.4 mil. for fiscal first quarter (ended April 30), Gucci reports June 21. Yves Saint Laurent cosmetics sales increased 15.9% to $40 mil., while fragrance revenues were off 1% at $60.9 mil. Gucci purchased Sanofi's beauty business, which included YSL and couture, from Artemis, a holding company for Pinault-Printemps-Redoute, in November (1"The Rose Sheet" Nov. 22, 1999, p. 4). LVMH and PPR have engaged in talks to resolve disagreements surrounding PPR's alliance with Gucci. The two companies had been negotiating a sale of LVMH's 20 mil. Gucci shares for $100 per share, but the deal fell through
You may also be interested in...
Gucci Acquires $583.4 Mil. Sanofi Beauty Business From Artemis
Gucci is purchasing Sanofi Beaute from Artemis for $1 bil., giving the fashion house Yves Saint Laurent fragrances and cosmetics, Roger & Gallet, and fragrance licenses for Van Cleef & Arpels, Oscar de la Renta, Fendi and Krizia. Sanofi beauty sales total $583.4 mil.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.